Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 106910
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106910
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.106910
Study of serum tumor markers in the early diagnosis of pancreatic cancer
Qian-Xi Deng, Guo-Jun Yuan, Qin Jian, Department of Gastroenterology, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang 621000, Sichuan Province, China
Xue-Li Tang, Department of Science and Technology, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang 621000, Sichuan Province, China
Xian-Hong Chen, Department of Gastroenterology, The People’s Hospital of Longchang, Neijiang 642150, Sichuan Province, China
Lin-Ju Wu, Department of Anesthesiology, The Third Hospital of Mianyang (Sichuan Mental Health Center), Mianyang 621000, Sichuan Province, China
Co-first authors: Qian-Xi Deng and Xue-Li Tang.
Author contributions: Deng QX, Tang XL, Yuan GJ, Jian Q, Chen XH, and Wu LJ designed and coordinated the study; Deng QX and Tang XL contributed equally to this article, they are the co-first authors of this manuscript; Yuan GJ, Jian Q, and Chen XH performed the experiments, acquired and analyzed data; Wu LJ reviewed and edited the manuscript; Deng QX and Tang XL wrote the manuscript; and all authors approved the final version of the article.
Institutional review board statement: This study was approved by the Medical Ethics Committee of the Third Hospital of Mianyang, approval No. 2024-shen (13).
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The original anonymous dataset is available on request from the corresponding author at wulinju2149@mysyy.cn. Participants gave informed consent for data sharing.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lin-Ju Wu, Chief Physician, Department of Anesthesiology, The Third Hospital of Mianyang (Sichuan Mental Health Center), No. 190 East Jiannan Road, Youxian District, Mianyang 621000, Sichuan Province, China. wulinju2149@mysyy.cn
Received: April 30, 2025
Revised: June 3, 2025
Accepted: July 23, 2025
Published online: September 15, 2025
Processing time: 137 Days and 17.6 Hours
Revised: June 3, 2025
Accepted: July 23, 2025
Published online: September 15, 2025
Processing time: 137 Days and 17.6 Hours
Core Tip
Core Tip: Serum levels of soluble intercellular adhesion molecule-1 and chitinase-3-like protein 1 are markedly elevated in pancreatic cancer patients, with these biomarkers showing strong correlations with tumor invasiveness, metastatic potential, and patient prognosis. This study is to investigate the value of serum tumour markers in combination with serum soluble intercellular adhesion molecule-1 and serum chitinase-3-like protein 1 in the early diagnosis of pancreatic cancer. The combined detection can significantly improve the accuracy and sensitivity of the diagnosis of pancreatic cancer and its different stages, providing a new effective concept for the early diagnosis of pancreatic cancer.